If these future events follow the patterns observed in the two aforementioned ELND trials, 2, 3 there might be more recurrences in the nodal observation arm over time than in the SLN biopsy arm.
We concentrated on long term (3years or more) recurrence-free females in order to assess HRQOL in a cohort that would not be biased by bladder cancer treatments.
In addition, high miR-21 expression level was found to be associated with poor response to adjuvant therapy and more rapid recurrence in patients with stage III disease.
Coit et al. reported similar nodal recurrence rates for SGD and CGD patients, while Singletary et al. reported relatively more nodal recurrence in SGD patients, but attributed that to the extent of tumor burden rather than the extent of surgery.
Although some authors report more local recurrence in patients with ILC after BCT [ 2, 73], most authors showed that there is no difference in DFS or OS after BCT in ILC versus IDC [ 74, 75].
In addition, higher miR-21 levels in primary tumours were correlated with shorter disease-free interval (Kulda et al, 2010) and high miR-21 expression was associated with poor response to adjuvant therapy and more rapid recurrence in patients with stage III disease (Schetter et al, 2008).
Three or more recurrences were observed in five individuals (Table 4).
For every 1,000 patients treated with dronedarone instead of amiodarone, we estimate approximately 228 more recurrences of AF in exchange for 9.6 fewer deaths and 62 fewer adverse events requiring discontinuation of drug.
More recurrences were seen in patients with irregularly shaped ITDs compared with patients with 1 or more smooth ITDs present.
Also within stage III, more recurrences were observed in ITD-positive patients compared with ITD-negative patients (65.1 vs. 39.1%, respectively).
